FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074404879> ?p ?o ?g. }

• W2074404879 endingPage "e15980" @default.
• W2074404879 startingPage "e15980" @default.
• W2074404879 abstract "Background To investigate the predictive significance of KRAS, BRAF, PIK3CA mutational status, AREG- EREG mRNA expression, PTEN protein expression and skin rash in metastatic colorectal cancer (mCRC) patients treated with cetuximab containing salvage chemotherapy. Methods Primary tumors from 112 mCRC patients were analyzed. The worst skin toxicity during treatment was recorded. Results KRAS, BRAF and PIK3CA mutations were present in 37 (33%), 8 (7.2%) and 11 (9.8%) cases, respectively, PTEN was lost in 21 (19.8%) cases, AREG and EREG were overexpressed in 48 (45%) and 51 (49%) cases. In the whole study population, time to tumor progression (TTP) and overall survival (OS) was significantly lower in patients with KRAS (p = 0.001 and p = 0.026, respectively) or BRAF (p = 0.001 and p<0.0001, respectively) mutant tumors, downregulation of AREG (p = 0.018 and p = 0.013, respectively) or EREG (p = 0.002 and p = 0.004, respectively) and grade 0-1 skin rash (p<0.0001 and p<0.0001, respectively). In KRAS wt patients TTP and OS was significantly lower in patients with BRAF (p = 0.0001 and p<0.0001, respectively) mutant tumors, downregulation of AREG (p = 0.021 and p = 0.004, respectively) or EREG (p = 0.0001 and p<0.0001, respectively) and grade 0-1 skin rash (p<0.0001 and p<0.0001, respectively). TTP was significantly lower in patients with PIK3CA mutations (p = 0.01) or lost PTEN (p = 0.002). Multivariate analysis revealed KRAS (Hazard Ratio [HR] 4.3, p<0.0001), BRAF mutation (HR: 5.1, p<0.0001), EREG low expression (HR: 1.6, p = 0.021) and absence of severe/moderate skin rash (HR: 4.0, p<0.0001) as independent prognostic factors for decreased TTP. Similarly, KRAS (HR 2.9, p = 0.01), BRAF mutation (HR: 3.0, p = 0.001), EREG low expression (HR: 1.7, p = 0.021), absecence of severe/moderate skin rash (HR: 3.7, p<0.0001) and the presence of undifferantited tumours (HR: 2.2, p = 0.001) were revealed as independent prognostic factors for decreased OS. Conclusions These results underscore that KRAS-BRAF mutations and EREG expression can be used as biomarkers to further select patients undergoing anti-EGFR treatment." @default.
• W2074404879 created "2016-06-24" @default.
• W2074404879 creator A5005031339 @default.
• W2074404879 creator A5012832857 @default.
• W2074404879 creator A5016502765 @default.
• W2074404879 creator A5019577278 @default.
• W2074404879 creator A5031993163 @default.
• W2074404879 creator A5035832029 @default.
• W2074404879 creator A5050556381 @default.
• W2074404879 creator A5071514902 @default.
• W2074404879 creator A5076020369 @default.
• W2074404879 creator A5077410158 @default.
• W2074404879 creator A5078192662 @default.
• W2074404879 creator A5081984487 @default.
• W2074404879 creator A5086401849 @default.
• W2074404879 date "2011-01-20" @default.
• W2074404879 modified "2023-10-16" @default.
• W2074404879 title "Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients" @default.
• W2074404879 cites W1525985826 @default.
• W2074404879 cites W1966147445 @default.
• W2074404879 cites W1969730641 @default.
• W2074404879 cites W1992786284 @default.
• W2074404879 cites W1999250974 @default.
• W2074404879 cites W2028035144 @default.
• W2074404879 cites W2029104788 @default.
• W2074404879 cites W2029684529 @default.
• W2074404879 cites W2057822920 @default.
• W2074404879 cites W2074473619 @default.
• W2074404879 cites W2081976008 @default.
• W2074404879 cites W2095201384 @default.
• W2074404879 cites W2095860691 @default.
• W2074404879 cites W2097121246 @default.
• W2074404879 cites W2097709626 @default.
• W2074404879 cites W2098223440 @default.
• W2074404879 cites W2098354753 @default.
• W2074404879 cites W2100490225 @default.
• W2074404879 cites W2100589633 @default.
• W2074404879 cites W2101995865 @default.
• W2074404879 cites W2103414735 @default.
• W2074404879 cites W2106789440 @default.
• W2074404879 cites W2106983577 @default.
• W2074404879 cites W2110803737 @default.
• W2074404879 cites W2114048774 @default.
• W2074404879 cites W2120490763 @default.
• W2074404879 cites W2122885616 @default.
• W2074404879 cites W2125229905 @default.
• W2074404879 cites W2127640925 @default.
• W2074404879 cites W2131413118 @default.
• W2074404879 cites W2135800465 @default.
• W2074404879 cites W2142564546 @default.
• W2074404879 cites W2144425748 @default.
• W2074404879 cites W2148156299 @default.
• W2074404879 cites W2155311724 @default.
• W2074404879 cites W2163799638 @default.
• W2074404879 cites W2164837623 @default.
• W2074404879 cites W2165132869 @default.
• W2074404879 cites W2168213749 @default.
• W2074404879 cites W2168377135 @default.
• W2074404879 cites W2314927739 @default.
• W2074404879 cites W4238448376 @default.
• W2074404879 cites W2002392289 @default.
• W2074404879 doi "https://doi.org/10.1371/journal.pone.0015980" @default.
• W2074404879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3024325" @default.
• W2074404879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21283802" @default.
• W2074404879 hasPublicationYear "2011" @default.
• W2074404879 type Work @default.
• W2074404879 sameAs 2074404879 @default.
• W2074404879 citedByCount "117" @default.
• W2074404879 countsByYear W20744048792012 @default.
• W2074404879 countsByYear W20744048792013 @default.
• W2074404879 countsByYear W20744048792014 @default.
• W2074404879 countsByYear W20744048792015 @default.
• W2074404879 countsByYear W20744048792016 @default.
• W2074404879 countsByYear W20744048792017 @default.
• W2074404879 countsByYear W20744048792018 @default.
• W2074404879 countsByYear W20744048792019 @default.
• W2074404879 countsByYear W20744048792020 @default.
• W2074404879 countsByYear W20744048792022 @default.
• W2074404879 crossrefType "journal-article" @default.
• W2074404879 hasAuthorship W2074404879A5005031339 @default.
• W2074404879 hasAuthorship W2074404879A5012832857 @default.
• W2074404879 hasAuthorship W2074404879A5016502765 @default.
• W2074404879 hasAuthorship W2074404879A5019577278 @default.
• W2074404879 hasAuthorship W2074404879A5031993163 @default.
• W2074404879 hasAuthorship W2074404879A5035832029 @default.
• W2074404879 hasAuthorship W2074404879A5050556381 @default.
• W2074404879 hasAuthorship W2074404879A5071514902 @default.
• W2074404879 hasAuthorship W2074404879A5076020369 @default.
• W2074404879 hasAuthorship W2074404879A5077410158 @default.
• W2074404879 hasAuthorship W2074404879A5078192662 @default.
• W2074404879 hasAuthorship W2074404879A5081984487 @default.
• W2074404879 hasAuthorship W2074404879A5086401849 @default.
• W2074404879 hasBestOaLocation W20744048791 @default.
• W2074404879 hasConcept C121608353 @default.
• W2074404879 hasConcept C126322002 @default.
• W2074404879 hasConcept C143998085 @default.
• W2074404879 hasConcept C190283241 @default.
• W2074404879 hasConcept C207103383 @default.

• next